相关实验视频
Updated: Jun 15, 2025

06:33
Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
Published on: June 9, 2018
7.7K
三烯二烯作为抗阿尔茨海默氏症疾病的保护因素
Camilla Corino1, Alberto Aimo2,3, Marco Luigetti4
1Health Sciences Interdisciplinary Center, Scuola Superiore Sant'Anna, Piazza Martiri Della Libertà 33, 56127, Pisa, Italy.
Molecular neurobiology
|August 27, 2024
概括
晶氨酸 (TTR) 在阿尔茨海默病 (AD) 中显示出神经保护潜力,通过防止粉样β (Aβ) 斑块的形成和增强清除. 稳定TTR可能是缓解AD进展和认知衰退的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 晶氨酸 (TTR) 是一种具有新兴神经保护作用的运输蛋白.
- 阿尔茨海默病 (AD) 的特点是氨基酸β (Aβ) 沉积和神经毒性.
- TTR与Aβ的相互作用是AD治疗研究的关键领域.
研究的目的:
- 在阿尔茨海默氏症 (AD) 中探索Transthyretin (TTR) 的神经保护机制.
- 审查TTR在预防粉样β (Aβ) 纤维素形成和促进其清除中的作用的证据.
- 讨论TTR稳定剂作为AD的潜在治疗策略.
主要方法:
- 文献审查和综合实验证据.
- 对TTR与粉胺β (Aβ) 的相互作用进行分析.
- 探索TTR稳定作为一种治疗方法.
主要成果:
- TTR可以防止粉样β (Aβ) 纤维的形成,并促进其从大脑清除.
- 在AD模型中,增强的TTR稳定性与缓解的神经退行和认知衰退相关.
- 小分子TTR稳定剂在增强Aβ结合和清除方面表现有前途.
结论:
- 晶氨酸 (TTR) 是阿尔茨海默氏病 (AD) 中的一个重要的神经保护因子.
- 稳定TTR为AD治疗提供了一个有前途的治疗途径.
- 对基于TTR的疗法进行进一步的研究对于AD干预是有必要的.
相关概念视频
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Enzyme-linked Receptors
77.7K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
77.7K
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
Role of Neurotransmitters in Memory
488
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
488
Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K

